AI assistant
Cellectar Biosciences, Inc. — Director's Dealing 2023
Dec 13, 2023
35021_dirs_2023-12-12_9cef66d1-cbf9-48ec-8eff-c3df7557ab1f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2023-06-23
Reporting Person: Longcor Jarrod (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-08 | Common Stock | A | 42927 | — | Acquired | 53141 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-23 | Stock option (right to buy) | $1.68 | A | 144000 | Acquired | 2033-01-17 | Common Stock (144000) | Direct |
Footnotes
F1: This option was contingently granted on January 16, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2023 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 23, 2023. Because January 16, 2023 was a federal holiday, the option was priced on the following trading day.
F2: This option shall vest over a period of three years from January 17, 2023, with 1/3 vesting on the first anniversary of January 17, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of January 17, 2023.